Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
- Details
- Category: AstraZeneca
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today presented positive detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody drug conjugate (ADC) and potential new medicine, in patients with HER2-positive metastatic breast cancer who received two or more prior HER2-targeted regimens.
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters
- Details
- Category: Novartis
Novartis holded an investor event in London to provide a comprehensive overview of the company’s progress in advancing its industry-leading R&D pipeline.
Vas Narasimhan, CEO of Novartis, said “Novartis had a year of breakthrough innovation in 2019, with five potential blockbuster NME approvals. The near term brings yet another catalyst-rich period with pipeline progress across the portfolio that can sustain long-term growth.
Roche and Spark Therapeutics, Inc. announce extension of tender offer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock (the "Shares") of Spark for USD 114.50 per Share, net to the seller thereof in cash, without
AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
- Details
- Category: Business
Today, Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), announced a multi-year strategic collaboration with Novartis to reimagine this leading pharmaceutical company's core pharmaceutical manufacturing, supply chain, and delivery operations using AWS's portfolio of cloud services.
AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
- Details
- Category: AstraZeneca
AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the US and Canada.
FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2)
Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
- Details
- Category: AstraZeneca
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC).
More Pharma News ...
- Bayer selects Pharmaron as partner organization
- FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy
- Amgen completes acquisition of Otezla® (apremilast)
- Bristol-Myers Squibb completes acquisition of Celgene, creating a leading biopharma company
- Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa
- Amgen and the Duke Clinical Research Institute announce initiation of first large-scale registry to evaluate real-world lipid management and the effectiveness of PCSK9 inhibitors
- Bristol-Myers Squibb and Pfizer announce randomized, controlled trial to evaluate the effect of atrial fibrillation screening on health outcomes in older individuals